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Coccidioides immitis, the primary pathogenic fungus that causes coccidioidomy-
cosis, is most commonly found in the deserts of the southwestern United States and
Central and South America. During the early 1990s, the incidence of coccidioidomycosis
in California increased dramatically. Even though most infections are subclinical or self-
limited, the outbreak is estimated to have cost more than $66 million in direct medical
expenses and time lost from work in Kern County, California, alone. In addition to the
financial loss, this pathogen causes serious and life-threatening disseminated infec-
tions, especially among the immunosuppressed, including AIDS patients. This article
discusses factors that may be responsible for the increased incidence of coccidioidomy-
cosis (e.g., climatic and demographic changes and the clinical problems of coccidioido-
mycosis in the immunocompromised) and new approaches to therapy and prevention.
Emerging infectious diseases have been defined
as “infections that have newly existed in a popula-
tion or have existed but are rapidly increasing in
incidence or geographic range” (1). In what sense is
coccidioidomycosis an emerging infectious disease?
Coccidioidomycosis is not a new disease; it was first
recognized and reported slightly more than 100
years ago by a medical student in Argentina (2). In
fact, coccidioidomycosis has affected inhabitants of
the desert Southwest for thousands of years (3).
However, in the past several years, the number of
cases of coccidioidomycosis has increased dramati-
cally, and the clinical symptoms of this illness
have changed in patients with acquired im-
munodefficiency syndrome (AIDS). In this article,
we explore some of the reasons for the increased
incidence of coccidioidomycosis, review the new clini-
cal data, and discuss current approaches to therapy
and prevention.
Etiology
Coccidioidomycosis is caused by Coccidioides
immitis, a dimorphic fungus that grows as a mold
in the soil. The mold forms arthroconidia within the
hypha, a type of conidia formation known as
enteroarthric development (Figure 1) (4). C. immitis
is the only species within the primary pathogenic
fungi that has this type of conidia development. Al-
ternate conidia undergo autolysis, leaving empty
spaces between viable arthroconidia. The arthro-
conidia are released into the atmosphere when the
wind ruptures the hypha. C. immitis  infects hu-
mans and animals almost exclusively by the
respiratory route (5). Once inhaled, the arth-
roconidia cluster in the lungs and undergo a
dramatic morphologic change. The round cells,
which develop into spherules, undergo repeated in-
ternal divisions until they are filled with hundreds
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process occurs over 48 to 72 hours (6). When the
spherule ruptures, each released endospore has the
capacity to develop into a mature spherule.
Epidemiology
C. immitis is primarily found in desert soil. It is
present in highest numbers in the San Joaquin Val-
ley in California, southern Arizona,  southern New
Mexico, west Texas, and the desert areas of north-
ern Mexico (Figure 2). The organism is also found
in scattered foci in coastal southern California,
southern Nevada, and Utah (7) and is endemic in a
few areas in Central and South America, especially
in Venezuela (7). C. immitis is distributed unevenly
in the soil and seems to be concentrated around
animal burrows and ancient Indian burial sites (8,9);
it is usually found 4 to 12 inches below the surface
of the soil (7).
Since C. immitis infects humans by the respira-
tory route, exposure to dust is one critical factor
determining the risk for infection (10). Coccidioido-
mycosis is not spread from person to person, except
in extraordinary circumstances. Coccidioidomycosis
probably had its most profound effect on the popu-
lation of the United States during World War II when
several training airfields were built in the San
Joaquin Valley. The rate of new infections in mili-
tary personnel was 8% to 25% per year (10).
Coccidioidomycosis was the most common cause of
hospitalization at many airbases in the South-
west. Though the death rate was very low, many
soldiers were sick for weeks to months, and their
training was completely disrupted. At least in part
because of efforts to minimize dust, the infection
rate declined as the war went on (10).
The incidence of coccidioidomycosis varies with
the season; it is highest in late summer and early
fall when the soil is dry and the crops are harvested
(10). If it rains at this time of the year (which is
unusual in southern California), disease incidence
declines as the amount of dust decreases. Dust
storms are frequently followed by outbreaks of coc-
cidioidomycosis. One particularly severe dust storm
in 1977 carried dust from the San Joaquin Valley
up to the San Francisco Bay area and resulted in
hundreds of cases of nonendemic coccidioidomyco-
sis in areas north of the San Joaquin Valley (11).
More recently, an earthquake centered in North-
ridge, California, was associated with 170 cases of
acute coccidioidomycosis in Ventura County, which
normally has a low incidence of this disease. The
airborne dust associated with landslides triggered
by the earthquake was implicated in the increase
in the number of cases (12).
Occupational or recreational exposure to dust is
also an important consideration. Agricultural work-
ers, construction workers, or others (such as
archeologists) who dig in the soil in the disease-
endemic area are at increased risk for the disease
(13,14). During World War II, C. E. Smith, one of
the most perceptive and influential epidemiologists
to study coccidioidomycosis, recommended dust con-
trol as a primary measure to reduce risk for exposure
(10). However, because the desert is inherently dusty,
many cases of coccidioidomycosis are acquired just
by driving through the disease-endemic area.
Clinical Illness
C. immitis is transmitted by the respiratory
route. Smith et al., in a prospective study of cases of
coccidioidomycosis acquired during World War II by
soldiers at three San Joaquin Valley airbases, skin-
tested the airmen periodically and questioned them
about illnesses in the interval. They found that most
infections (60%) were asymptomatic and resolved
spontaneously; 15% were not severe enough to re-
quire medical care, and 25% were clinically
important and required a substantial amount of time
off work (15). In symptomatic patients, the pulmo-
nary illness ranges from a self-limited flulike illness
to pneumonia (16). Approximately 5% of primary in-
fections result in erythema nodosum or erythema
marginatum with associated noninfectious arthri-
tis; most of those patients have a self-limited
infection (17). Particularly in persons with diabe-
Figure 2. The geographic distribution of coccidioidomyco-
sis. Cross-hatching indicates the heavily disease- endemic
area, single hatching, the moderately disease- endemic
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tes, multiple thin-walled chronic cavities tend to
develop as a residual effect of pulmonary
coccidioidomycosis (18). Unlike in tuberculosis, in
coccidioidomycosis, dissemination almost always be-
comes evident within a few weeks of the primary
pneumonia, although in cases of limited dissemina-
tion it may not become clinically evident until
months later (15,19). Coccidioidomycosis can dis-
seminate and cause miliary disease, bone and joint
infection, skin disease, soft tissue abscesses, and
meningitis (15,16). These extrapulmonary compli-
cations are uncommon (<5% of infections).
The risk for disseminated coccidioidomycosis is
much higher among some ethnic groups, particu-
larly African-Americans and Filipinos.  In these
ethnic groups, the risk for disseminated coccidio-
idomycosis is tenfold that of the general population
(5,20). Presumably, a gene (or genes) that increases
susceptibility to infection is more prevalent in these
ethnic groups than in the general population. Such
a resistance gene has been identified in mice (21-
23), but not yet in humans. The mechanism by which
the resistance genes affect the course of the disease
in mice is not clear. Pregnant women and the im-
munosuppressed are also at high risk for developing
disseminated disease (Figure 3) (24). One study dem-
onstrated that the growth rate of spherules was
influenced by human sex hormones, which may par-
tially account for the increased risk of disseminated
disease in pregnancy (25). Pregnancy also redirects
the immune response toward humeral (TH2) immu-
nity and away from delayed hypersensitivity (TH1)
(26), which may influence resolution of coccidioido-
mycosis. Generalized suppression of cell mediated
immunity also increases the risk of disseminated
disease (27).  Coccidioidomycosis is particularly se-
vere in patients with organ transplants or AIDS.
Though disseminated coccidioidomycosis is un-
common, and symptomatic coccidioidal pneumonia
usually resolves without therapy, many of these
patients are very ill for weeks to months.  Galgiani
reported that a group of college students in Tucson
who had coccidioidomycosis required an average of
six clinic visits before the disease resolved (16).
Therefore, this can be an expensive illness in terms
of medical costs and time lost from work or school,
even when the infection resolves spontaneously.
Coccidioidomycosis Epidemic in California
Kern County, in the San Joaquin Valley,
California, is one of the most highly coccidioidomy-
cosis-endemic regions. The number of new cases of
coccidioidomycosis in the area has varied widely
from year to year; a low incidence of coccidioidomy-
cosis from 1987 to 1990 (<500 reported cases a year
in Kern County), was followed by a high incidence
from 1991 to 1994 (28-30). The number of reported
cases, which were identified by serologic testing at
the Kern County Health Department (the reference
serology laboratory for the county), probably repre-
sent approximately 10% of the total number of
infected persons in that county (Figure 4) (28). The
medical costs for infected persons in Kern County
are estimated at $66 million (29). In 1992, 4,500 new
cases were reported to the California State Depart-
ment of Health Services (30), most from Kern
County; the number of  new cases also increased in
almost all counties in central and southern Califor-
nia (30). The increase in reported cases in California
in 1991-92  was dramatic but certainly an under-
estimate of the magnitude of the problem (31).
The epidemic seems to be waning, for reasons
that are not clear, but the marked increase in inci-
dence from the 1980s to 1991 through 1993 is
indisputable. What factors may account for this in-
crease? One major consideration is the weather.
C. E. Smith  observed years ago that the number of
cases of coccidioidomycosis was higher in the sum-
mer after a rainy winter than after a dry winter
(10). In March 1991, a 5-year drought in California
ended with a heavy rainfall. Rainfall was also heavy
in the winters of 1992 and 1993. Though the rela-
tionship between the weather and the density of C.
immitis in the soil may never be understood in de-
tail, the following scenario seems plausible. During
drought years, the number of organisms competing
with C. immitis decreases. C. immitis does not
thrive, but it remains viable though dormant. After Figure 3. The most common clinical presentations of coc-
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heavy rain, the arthrocondia germinate and multi-
ply to a higher density than usual because of the
lack of competing organisms. Once the soil dries in
the late summer and fall, the arthroconidia become
airborne and potentially infectious (29).
Another reason for the sudden increase in dis-
ease incidence might have been the number of
susceptible persons in the disease-endemic area. The
number may have been the result of both increased
migration of susceptible persons and decreased im-
munity in the indigenous population. Immunity
comes from prior infection and is manifest as a posi-
tive coccidioidin skin test. In almost all cases,
coccidioidomycosis confers lifelong immunity. As a
result of years of low incidence, the number of
nonimmune persons may have increased, as evi-
denced by the decrease in prevalence of positive
coccidioidin skin tests among local high school stu-
dents. In 1939, 50% to 60% of high school students
in the San Joaquin Valley had positive skin tests
(17), but in the 1980s only 3% to 5% of high school
students had positive skin tests (T. Larwood, pers.
comm.). Given the historical data, this estimate
seems low, but another study also found a low preva-
lence. In 1985, workers in Tucson estimated that
30% of a random sample of persons in a Hispanic
neighborhood had positive skin tests (32). In addi-
tion to the drought, irrigation of fields, the increasing
amount of land under cultivation, and a decrease in
indoor dust due to the widespread use of air condi-
tioning may also have played a role in the relatively
low incidence of infections in the 1980s.
Coccidioidomycosis in the Immunosuppressed
C. immitis is a primary pathogen that can cause
disease in immunologically healthy persons. In the
population as a whole, fewer than 5% of infected
persons have persistent pulmonary infection or
extrapulmonary dissemination of the disease (16).
The incidence of clinically significant disease in im-
munosuppressed patients is much higher. In one
study symptomatic coccidioidomycosis developed in
18 (7%) of 260 renal transplant patients in Arizona
over a 10-year period, primarily in the first year af-
ter transplantation (33). This rate was substantially
higher than the rate of infection in patients who were
undergoing hemodialysis. Approximately 12 (67%)
of infections in the patients with renal transplants
were disseminated; the remainder were confined to
the lung. Of patients with disseminated disease, 10
(83%) died, despite intensive therapy with amph-
otericin B. In another study from Tucson, all
confirmed cases of coccidioidomycosis during a 4-
year period were reviewed. The dissemination rate
was 8 (73%) of 11 of patients who were receiving
immunosuppressive therapies, compared with only
15 (14%) of 110 healthy controls (34). As more pa-
tients in the disease-endemic area receive liver, lung,
and heart transplants, this problem will increase.
Pregnant women, especially those in the third
trimester, are at high risk for developing dissemi-
nated coccidioidomycosis if they become infected
(24). In the first and second trimesters, the risk is
much lower. The reason is not entirely clear, but two
factors may play a role: 1) the high sex hormone
levels found in late pregnancy enhance the growth
of C. immitis in vitro (25), and 2) the shift in the T-
cell immune response late in pregnancy toward TH2
cytokines (26) interferes with resolving the infec-
tion. In experimental animals, pregnancy increases
the severity of leishmaniasis, another infection that
is controlled by a TH1 T-cell response (35).
Coccidioidomycosis in AIDS patients is also very
likely to be life-threatening. The first cases of coc-
cidioidomycosis described in AIDS patients were
atypical, with a reticulonodular chest x-ray pattern,
positive blood cultures, and infection of multiple
organs (36).  As we have gained more experience
with coccidioidomycosis in HIV-infected persons, we
have learned that the clinical spectrum is broader
than originally reported. Fish and his colleagues
collected data from 77 AIDS patients with coccidio-
idomycosis who were treated by physicians in
Arizona and California (37). They grouped the pa-
tients according to their clinical symptoms (Figure
5).
Although the largest group of patients had dif-
Figure 4. The number of new cases of coccidioidomycosis
identified by serologic testing at the Kern County Public
Health Laboratory (source of data: Dr. Ron Talbot). The
asterisk indicates a projected number.Vol. 3, No. 2—July-September 1996 Emerging Infectious Diseases
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fuse pulmonary infiltrates, a significant fraction had
focal pulmonary disease, meningitis, or other
extrapulmonary disease. Six patients had only a
positive serologic test with no other evidence of in-
fection. Excluding the patients who had only a
positive serologic test, 81% of the patients in this
series had a positive serologic test for coccidioido-
mycosis, either for IgM or IgG antibodies. However,
only 69% of patients with diffuse pulmonary dis-
ease had a positive serologic test, and the death rate
in this group was also the highest (70%). In all clini-
cal groups, death was correlated with the number
of circulating CD4 T-cells at the time of diagnosis.
For clinicians, however, the most important mes-
sage from this study is that coccidioidomycosis is
not a uniformly fatal complication in patients with
AIDS, and that many forms of this disease, includ-
ing meningitis, respond to therapy. Patients with
<200 CD4 T-cells/µl are more likely to have severe,
disseminated infections.
A more recent prospective study of 170 HIV-in-
fected persons in an area of Arizona where
coccidioidomycosis is endemic showed a cumulative
incidence of coccidioidomycosis of 25% over 41
months (38). The most important risk factors were
the level of CD4 T-cells and the diagnosis of AIDS
(as opposed to HIV infection). HIV-infected patients
with AIDS or <250 CD4 T-cells/µl were 8 to 35 times
more likely to get coccidioidomycosis. History of coc-
cidioidomycosis, a history of a positive skin test for
coccidioidomycosis, or a prolonged stay in the dis-
ease-endemic area were not associated with an
increased risk for infection. These data suggest that
most cases were primary infections in severely im-
munosuppressed patients. Since patients with AIDS
were not more likely to be exposed to the spores of
C. immitis and all patients were seen prospectively
at 4-month intervals and tested for antibody to C.
immitis, severe immunosuppression appeared to
increase their risk for infection, as well as disease.
As in the retrospective study reviewed above, the
clinical symptoms varied widely, ranging from mild
to extremely severe. Only one patient had antibody
titers to C. immitis by complement fixation test with-
out any other evidence of disease.
Treatment
Various drugs are now available for treating coc-
cidioidomycosis. In addition to amphotericin B,
which must be given intravenously and is consider-
ably toxic, triazole compounds have been found to
be active agents for treating most manifestations of
coccidioidomycosis. Fluconazole, in an uncontrolled
study, was reported to be effective primary therapy
for coccidioidal meningitis; since untreated
coccidioidal meningitis is uniformly fatal, robust con-
clusions could be drawn from this trial (39).
Forty-seven consecutive patients were treated with
400 mg/day of fluconazole; during the first 6 months
of therapy, 33 (70%) of the patients responded to
therapy. (A response was defined as a 40% reduc-
tion in a score, on the basis of clinical measurements
and cerebrospinal fluid findings.) Two patients who
did not respond to therapy died of coccidioidomyco-
sis; both were HIV-positive. Because of previous
experience with high relapse rates when azole
therapy is stopped, the authors recommended life-
long treatment with fluconazole. In a small study,
four of five patients treated for meningitis with
itraconazole as sole therapy responded favorably
(40). A recent article emphasized the high relapse
rate after azole therapy is stopped (41). The alter-
native treatment to the azoles is amphotericin B. If
amphotericin B is used to treat meningitis, however,
it must be given intrathecally as well as intrave-
nously, and this greatly increases the risk for a toxic
reaction to that drug.
Clearly, fluconazole and itraconazole can be used
to treat patients with nonmeningeal coccidioidomy-
cosis (42-44). Whether one of these drugs is superior
Figure 5. The most common clinical presentations of coc-
cidioidomycosis in AIDS patients. The group “Others”
includes dissemination to the lymph nodes, liver, spleen,
and bone marrow. The antibody only group includes pa-
tients with serologic evidence of infection but no evident
focus of infection. Since these were passively collected
cases, a protocol to search for inapparent sites of infec-
tion had not been agreed upon (37).Vol. 2, No. 3—July-September 1996 Emerging Infectious Diseases 197
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to the other, or how either one compares to
amphotericin B is not known. It seems prudent to
treat extremely ill patients with amphotericin B, at
least until their clinical situation stabilizes, although
no published studies support that point of view.
However, few (if any) patients with the acute mil-
iary form of coccidioidomycosis have been included
in any of the reported studies of any of the azole
drugs. New agents that are more active against coc-
cidioidomycosis are still sorely needed.
Prevention
Simple environmental measures, such as plant-
ing grass or paving roads in highly populated areas,
decrease the amount of airborne dust and lower the
risk for coccidioidomycosis (10). These measures do
not necessarily eradicate C. immitis from the soil
but lower the risk for airborne dispersion of the or-
ganism. At present, no practical method exists for
eliminating C. immitis from the soil.
Vaccine Development
An alternative approach is to vaccinate persons
at risk. A vaccine is feasible because natural infec-
tion almost always confers lifelong immunity from
reinfection. Furthermore, good animal models exist
to test vaccine candidates (21). Finally, genetically
susceptible mice can be successfully immunized,
which suggests that the genetically susceptible hu-
man population would also benefit from vaccination
(21).
One vaccine that has been tested is a killed
spherule vaccine developed by Pappagianis and
Levine. It protected mice and other animals from
experimental infection with C. immitis (45). Between
1980 and 1985, a double-blinded human study com-
pared results of a formalin-killed spherule vaccine
with results obtained from a placebo. In this study,
which involved almost 3,000 people, only a minority
of the vaccinated persons had positive skin test re-
sults to C. immitis. Although the incidence of
coccidioidomycosis was low while this study was con-
ducted, no difference was found in the number of
cases of coccidioidomycosis or the severity of the dis-
ease in the vaccinated group compared with that
for the placebo-receiving control group (46). One
explanation for the ineffectiveness of this vaccine
may be that relatively small numbers of killed or-
ganisms could be injected into human without
unacceptable local side effects of pain and swelling.
Nevertheless, the vaccine trial made it clear that
immunization with tolerable numbers of whole
killed-spherules does not provide immunoprotection
against coccidioidomycosis in humans.
Since the cell wall of C. immitis is made up pri-
marily of nonprotein macromolecules, it contains a
large amount of material presumably nonantigenic
for T lymphocytes. Therefore, the whole organism is
not the ideal vaccine candidate. Ideally, one would
like to vaccinate patients selectively only with anti-
gens that stimulate a protective T-cell-mediated
immune response. These antigens have been diffi-
cult to identify, and a consensus on what they are
does not exist. Various approaches have been used
to obtain antigenic proteins. In one, a lysate of
arthroconidia (coccidioidin) or spherules (spherulin)
was made (47). Alkali treatment has also been used
to extract antigens from arthroconidia and spherules
(48). Another approach has been to use C. immitis
antigens obtained without extraction or autolysis.
The advantage of this method is that one should
obtain reproducible preparations of intact proteins.
Cole and co-workers (49) found that when the outer
conidial wall was removed from arthroconidia, the
organism released various proteins (called the
soluble conidial wall fraction). This mixture of pro-
teins was extraordinarily effective in stimulating the
proliferation of C. immitis-immune T cells in mice.
Another antigenic mixture is a membranous mate-
rial consisting primarily of proteins and lipids that
the spherule phase of the organism spontaneously
releases (the spherule outer wall). This spherule wall
fraction has been shown to be an active antigen in
T-cell-mediated immune responses in mice (50).
All of these mixtures are heterogeneous and dif-
ficult to fractionate biochemically. This is probably
due, at least in part, to differences in glycosylation,
which makes physically separating the proteins dif-
ficult. To resolve this problem, Galgiani and his
colleagues deglycosylated the proteins from a tolu-
ene spherule lysate by using hydrogen fluoride
(51,52). Although this treatment does remove all
sugars, it is extraordinarily harsh and yields less
than 10% of the initial protein, with most of the pro-
tein forming an insoluble precipitate. Nevertheless,
the resulting product reacts with reference antise-
rum to C. immitis in immunoelectrophoresis.  This
antigen also stimulated a proliferative T-cell re-
sponse in patient lymphocytes but not in those of
the control group (noninfected donors).
Another way to attack the problem of generating
pure  C. immitis antigens is to use molecular bio-
logic techniques. The advantage to this approach is
that once antigens are molecularly cloned, and the
protein is expressed, an essentially unlimited source
of completely defined antigen is available. There-
fore, one would not have to repeatedly grow C.
immitis, extract the antigen, and purify it from a
complex mixture. In addition, with the molecular198 Emerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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approach, antigens could be delivered as part of a
living vaccine system, should that be required to
effectively immunize people against coccidioidomy-
cosis. We believe that systematically identifying and
evaluating C. immitis T-cell reactive antigens in ex-
perimental animals is a rational approach to the
ultimate development of a vaccine. Our laboratories,
in collaboration with Garry Cole, have used a mu-
rine T-cell line that is specific for soluble conidial
wall fraction antigens to identify one cloned frag-
ment of a C. immitis protein (53). Recently, genomic
DNA clones coding for this protein have been iden-
tified and sequenced. Significant homology exists
between this C. immitis antigen and the human
enzyme 4 hydroxyphenylpyruvate dioxygenase (54).
This protein has been expressed in bacteria and was
found to elicit T-lymphocyte proliferative responses
in mice immune to C. immitis. We are testing its
efficacy as an experimental vaccine.
With the exception of alkali extracted spherules
(55) and whole killed spherules (45), none of the T-
cell reactive antigens have been shown to be
immunoprotective in experimental models. However,
it is reasonable to expect that some antigen, or mix-
ture of antigens, will be found that can confer
protective immunity in experimental animals. Mo-
lecular strategies are available to accomplish this
task and are an important area of future research.
Once a vaccine has been successfully tested in ani-
mals, another human vaccine trial would be feasible.
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